
MNK
Healthcare · Drug Manufacturers - Specialty & Generic · $4.5M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2020
EPS trend, 90 days to now · -8.9% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 9, 2023 | Before the open | — | -56.65 | — |
| May 9, 2023 | Before the open | — | -18.89 | — |
| Feb 28, 2023 | Before the open | — | -18.90 | — |
| Nov 8, 2022 | Before the open | — | -21.58 | — |
| May 3, 2022 | Time not confirmed | — | -1.42 | — |
| Mar 15, 2022 | Time not confirmed | — | -2.41 | — |
| Nov 2, 2021 | Time not confirmed | — | -3.18 | — |
| Aug 3, 2021 | Time not confirmed | — | -1.25 | — |
| May 4, 2021 | Time not confirmed | — | -1.70 | — |
| Aug 4, 2020 | Before the open | 1.34 | 1.89 | +41.0% |
| May 5, 2020 | Before the open | 1.43 | 1.64 | +14.7% |
| Feb 25, 2020 | Before the open | 2.06 | 2.40 | +16.5% |
| Nov 5, 2019 | Before the open | 1.97 | 2.07 | +5.1% |
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology,…
| Aug 6, 2019 |
| Before the open |
| 2.08 |
| 2.53 |
| +21.6% |
| May 7, 2019 | Before the open | 1.70 | 1.94 | +14.1% |
| Feb 26, 2019 | Before the open | 1.92 | 2.18 | +13.5% |
| Nov 6, 2018 | Before the open | 1.79 | 2.10 | +17.3% |
| Aug 7, 2018 | Before the open | 1.48 | 1.78 | +20.3% |
| May 8, 2018 | Before the open | 1.08 | 1.31 | +21.3% |
| Feb 27, 2018 | Before the open | 1.69 | 2.01 | +18.9% |